Tier 3 — preclinical

Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review

Fatemeh Pourteymour Fard Tabrizi, Fatemeh Hajizadeh-Sharafabad, Maryam Vaezi, Hamed Jafari-Vayghan, Mohammad Alizadeh, Vahid Maleki
Journal of ovarian research 2020 13(1):11

Bibliography

PubMed
PMID 32005271
PubMed Central
PMC6993490
DOI
10.1186/s13048-020-0616-z
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that they have no competing interests.

Study snapshot

DesignSystematic review of mixed human and animal PCOS evidence
ModelMixed human and preclinical evidence synthesis
Sample8 reports: 5 animal studies and 3 clinical reports
InterventionQuercetin across clinical and experimental regimens
DurationSearches through March 2019
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2020, this source examined hormones and reproductive health. Design: Systematic review of mixed human and animal PCOS evidence. Sample/model: 8 reports: 5 animal studies and 3 clinical reports. The exposure or intervention was Quercetin across clinical and experimental regimens. Follow-up or treatment period: Searches through March 2019.

The review describes favorable hormonal, metabolic, and ovarian findings in parts of the literature, without consistent weight effects.

Animal ovarian outcomes are not human fertility outcomes. Few clinical reports and possible shared cohorts limit independent confirmation.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review describes favorable hormonal, metabolic, and ovarian findings in parts of the literature, without consistent weight effects.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin across clinical and experimental regimens; Searches through March 2019.

What this study can and cannot tell us

  • Animal ovarian outcomes are not human fertility outcomes. Few clinical reports and possible shared cohorts limit independent confirmation.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology